Skip to main content

Center for Applied Therapeutics

Photo of Herbert Kim Lyerly, MD

Herbert Kim Lyerly, MD

Office: 203 Research Drive, Medical Sciences Research Building, Suite 433, Durham, NC 27710
Phone: 919-681-8350

Scientific Focus

Dr. H. Kim Lyerly, M.D., F.A.C.S, is the Director for The Center for Applied Therapeutics. He is the George Barth Geller Professor in Cancer Research, Professor of Surgery, Associate Professor of Pathology and Assistant Professor of Immunology at Duke University in North Carolina. Dr. Lyerly is an internationally recognized expert in cancer therapy and immunotherapy and has published over 300 scientific articles and book chapters, and has edited 10 textbooks on surgery, cancer immunotherapy, and novel cancer therapies. 

The Center for Applied Therapeutics encompasses a broad array of research activities involved in the development, preclinical testing, and clinical testing of novel therapies targeting cancer or precancerous conditions.  Collectively, the Center for Applied Therapeutics consists of over 30 individuals ranging from senior scientists to post-doctoral fellows, which serves as a robust environment for research activity in a broad array of applied therapeutics. Major research areas of focus are:

Basic Sciences

  • Early Cancer Genomics and Biology

Translational and Clinical Sciences

  • In vivo Detection of Malignant Cells
  • Immune Therapy of Cancer

Population Sciences

  • Environmental Health Scholars
  • International/Global Studies

Selected Achievements

  1. The laboratory has been a pioneer in cancer immunotherapy, and has published and received peer reviewed funding for over 25 years.  We are currently working on a number of cancer immune strategies that include cancer vaccines, modulation of the local tumor microenvironment, and combination immunotherapy with checkpoint inhibitors.
  2. The laboratory has focused significant attention on the early detection and characterization of breast cancer.  We have a large research program in the genomic profiling of early and pre-invasive breast cancer as well the stromal and adaptive immune responses to early breast cancer.
  3. The laboratory has created an innovative informatics platform to process large data sets in search of new insights into genetic and environmental changes in individual health and population health.

Advanced Training

Individuals within the laboratory have the opportunity to participate in education and training available to Duke University faculty, staff and students. 

In addition to the Duke training, Dr. Lyerly leads an innovative regulatory sciences training program, the Accelerating Anticancer Agent Development and Validation Workshop held in Bethesda, Maryland, each spring (www.acceleratingworkshop.org).

Contact Us

203 Research Drive
Medical Sciences Research Building, Suite 433
Durham, NC 27710
Office phone: 919-681-8350
Email: Kim.Lyerly@Duke.edu

Latest Publications

Sun, Yuanyuan, Suya Wang, Hainan Yang, Jiangping Wu, Sha Li, Guoliang Qiao, Shuo Wang, et al. “Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth..” Immunotherapy 11, no. 11 (August 2019): 953–66. https://doi.org/10.2217/imt-2019-0055.

Full Text

Zhao, Y., G. Qiao, X. Wang, Y. Song, X. Zhou, N. Jiang, L. Zhou, et al. “Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS)..” Clin Transl Oncol 21, no. 6 (June 2019): 721–28. https://doi.org/10.1007/s12094-018-1968-3.

Full Text

Salgado, Roberto, David B. Solit, David L. Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, et al. “Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology..” Eur J Cancer 114 (June 2019): 128–36. https://doi.org/10.1016/j.ejca.2019.03.025.

Full Text

Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study..” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.

Full Text